Ninety-four percent were wake-up strokes. Median NIHSS score was 6. Median time from last known well to symptom recognition was 7 hours and to alteplase administration slightly over 10 hours. The primary end point of an mRS score 0 to 1 at 90 days was achieved in 53.3% of the alteplase group and in 41.8% of the placebo group (P=0.02). Only 20% had LVO of the intracranial internal carotid or proximal middle cerebral arteries.88 See Table XIX in online Data Supplement 1. 3.5.3. Mild Stroke COR LOE New, Revised, or Unchanged For otherwise eligible patients with mild but disabling stroke symptoms, IV alteplase is recommended for patients who can be treated within 3 hours of ischemic stroke symptom onset or patient last known well or at baseline state. I B-R Recommendation revised from 2015 IV Alteplase. COR and LOE added to conform with ACC/AHA 2015 Recommendation Classification System. For otherwise eligible patients with mild disabling stroke symptoms, IV alteplase may be reasonable for patients who can be treated within 3 and 4.5 hours of ischemic stroke symptom onset or patient last known well or at baseline state. IIb B-NR New recommendation. For otherwise eligible patients with mild nondisabling stroke symptoms (NIHSS score 0 5), IV alteplase is not recommended for patients who could be treated within 3 hours of ischemic stroke symptom onset or patient last known well or at baseline state. III: No Benefit B-R New recommendation. For otherwise eligible patients with mild non-disabling stroke symptoms (NIHSS 0 5), IV alteplase is not recommended for patients who could be treated within 3 and 4.5 hours of ischemic stroke symptom onset or patient last known well or at baseline state. III: No Benefit C-LD New recommendation. 